Study of Genotoxic Properties of Thiosonide
https://doi.org/10.21292/2075-1230-2021-99-6-22-27
Abstract
The objective of the study: evaluation of mutagenic properties of thiosonide in tests of chromosomal aberrations in mammalian bone marrow cells and mutation accounting on Salmonella typhimurium strains.
Subjects and methods. Studies were carried out using F1 hybrids of CBA×C57BL/6 mice, they received thiozonide in the equivalent of a therapeutic dose and 160 times above it, once and in the course of 5 injections. The genetic toxicity of thiosonide was evaluated on Salmonella typhimurium strains in the tested doses of 1,000, 100, 10, 1 and 0.1 μg per plate.
Results. No mutagenic activity of thiosonide in the chromosomal aberration counting test in bone marrow cells of mice was demonstrated. The level of chromosome aberrations in the experiment did not exceed the corresponding control values. Thus, thiosonide at the therapeutic dose (25 mg/kg) and 160-fold increase above it (4,000 mg/kg) did not induce chromosomal aberrations in the bone marrow cells of mice either with single dosing or several intragastric administrations.
According to the Ames test results, the number of revertant colonies in the solvent control in the CM- and CM+ variants was within the range of spontaneous fluctuations for these strains; thiosonide in all tested doses did not show mutagenic effect on the TA 100, TA 98, and TA 97 strains both with the system metabolic activation and without it.
About the Authors
A. Yu. Sаvchenko
Research Center of Biomedical Technologies, Federal Medical Biological Agency
Russian Federation
Russian Federation
Alla Yu. Savchenko – , Leading Researcher of Pharmacosimulation Laboratory.
1, Svetlye Gory Settlement, Moscow Region, 143442
M. S. Burenkov
AO Pharm-Sintez
Russian Federation
Russian Federation
Mikhail S. Burenkov – Candidate of Biological Sciences, Manager of Preclinical Studie .
2, Build. 46, the 2nd Kabelnaya St., Moscow, 111024.
P. S. Bаydin
AO Pharm-Sintez
Russian Federation
Russian Federation
Petr S. Baydin – Candidate of Medical Sciences, Head of Medical Department.
2, Build. 46, the 2nd Kabelnaya St., Moscow, 111024.
G. V. Rаmenskаya
Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Galina V. Ramenskaya I.M. – Doctor of Pharmaceutical Sciences, Director of Pharmacy Institute.
8, Bd. 2, Trubetskaya St., Moscow, 119991
N. V. Perovа
Institute of Medical Biological Information Technologies
Russian Federation
Russian Federation
Nadezhda V. Perova – Doctor of Biological Sciences, Deputy Director.
Bd. 2, 43/20, B. Tishinskiy Lane, Moscow, 123557.
V. G. Kukes
Research Center of Biomedical Technologies, Federal Medical Biological Agency, Clinical Pharmacology Branch
Russian Federation
Russian Federation
Vladimir G. Kukes – Doctor of Medical Sciences, Professor, Academician of RAS.
11, Yauzskaya St., Moscow, 109240, Russia.
References
1. Bocharova I.V., Burenkov M.S., Lepekha L.N., Smirnova T.G., Chernousova L.N., Demikhova O.V. Preclinical studies of the specific activity of the new anti-tuberculosis drug of thiosonide. Tuberculosis and Lung Diseases, 2014, no. 6, pp. 46-50. (In Russ.) doi.org/10.21292/2075-1230-2014-0-6-46-50.
2. Bykov V.V., Sedykh I.M., Bykova А.V. Mutagenicity assessment of a benzopentathiepine derivative in the Ames test. Laboratornye Zhivotnye Dlya Nauchnykh Issledovaniy, 2018, no. 4. (In Russ.) https://doi.org/10.29296/2618723X-2018-04-01.
3. Dorjhand Baldandorzh, Battsetseg Chojdash, Kupul Jalkhaa. Assessment of soils mutagenic activity in Erdenet. Acta Biomedica Scientifica, 2010, no. 6-1. (In Russ.) Available: https://cyberleninka.ru/article/n/otsenka-mutagennoy-aktivnosti-pochv-g-erdenet (Accessed: 26.12.2019).
4. Kolobrodova N.А., Snigur G.L., Kurkin D.V. Assessment of mutagenicity of a new antidiabetic agent using microplate format mutagenicity assay.Volgogradsky Nauchno-Meditsinsky Journal, 2015, no. 2 (46). (In Russ.) Available: https://cyberleninka.ru/article/n/opredelenie-mutagennosti-novogo-veschestva-s-antidiabeticheskim-deystviem-v-mikroplanshetnom-variante-testa-eymsa (Accessed: 26.12.2019).
5. Menshikova L.A. Farmakokineticheskoye issledovaniye originalnogo lekarstvennogo sredstva tiozonida. Diss. kand. farmatsevt. nauk. [Pharmacokinetic study of the original drug thiosonide. Cand. Diss.]. Moscow, 2016.
6. Nechaeva O.B. TB situation in Russia. Tuberculosis and Lung Diseases, 2018, vol. 96, no. 8, pp. 15-24. (In Russ.) https://doi.org/10.21292/2075-1230-2018-96-8-15-24.
7. Sterlikov S.А., Rusakova L.I., Son I.M. Treatment outcomes of extensive drug resistant tuberculosis: results of three-year follow-up. Sovremennye Problemy Zdravookhraneniya i Meditsinskoy Statistiki, 2018, no. 2, pp. 14-26. (In Russ.) Available: https://cyberleninka.ru/article/n/ishody-sluchaev-lecheniya-tuberkulyoza-s-shirokoy-lekarstvennoy-ustoychivostyu-rezultaty-tryohletnego-nablyudeniya (Accessed: 05.08.2019).
8. Yablonskiy P.K., Vinogradova T.I., Levashev Yu.N., Pavlova M.V., Zilber E.K., Starshinova А.А., Sapozhnikova N.V., Chernokhaeva I.V., Аrchakova L.I., Zabolotnykh N.V., Vitovskaya M.L. Nonclinical and clinical studies of the new anti-tuberculosis drug of Perchlozone®. CMAC, 2016, no. 1. (In Russ.) Available: https://cyberleninka.ru/article/n/doklinicheskie-i-klinicheskie-issledovaniya-novogo-protivotuberkuleznogo-preparata-perhlozon (Accessed: 12.12.2019).
9. Harris M., Taylor G. Medical statistics made easy. London, Taylor and Francis, 2006, 114 p.
10. Ford C.E., Hamerton J.L. The chromosomes of man. Nature, 1956, no. 178 (4541), pp. 1020-1023.
11. Keam S.J. Pretomanid: First Approval. Drugs, 2019, no. 79 (16), pp. 1797-1803. doi: 10.1007/s40265-019-01207-9.
12. Li Y., Sun F., Zhang W. Bedaquiline and delamanid in the treatment of multidrug-resistant tuberculosis: Promising but challenging. Drug. Dev. Res., 2019,no. 80 (1), pp. 98-105. doi: 10.1002/ddr.21498.
Review
For citations:
Sаvchenko A.Yu., Burenkov M.S., Bаydin P.S., Rаmenskаya G.V., Perovа N.V., Kukes V.G. Study of Genotoxic Properties of Thiosonide. Tuberculosis and Lung Diseases. 2021;99(6):22-27. (In Russ.) https://doi.org/10.21292/2075-1230-2021-99-6-22-27
Views:
575
Email this article 